Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DexBasal Study System in Type 2 Diabetes
NCT07681375Phase 1Active, not recruiting
- Sponsor
- Dexcom
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in type 2 diabetes mellitus (T2DM), sponsored by Dexcom. Primary endpoints: Measurement of participant safety while using the DexBasal Study System at 8 weeks, Measurement of system recommended dose at 8 weeks and 11 more. Started Apr 2023; status: active, not recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07681375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681375.